Premium
De novo donor‐specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
Author(s) -
Moayedi Yasbanoo,
Fan ChunPo S.,
Tinckam Kathryn J.,
Ross Heather J.,
McCaughan Jennifer A.
Publication year - 2018
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13416
Subject(s) - medicine , heart transplantation , human leukocyte antigen , donor specific antibodies , immunosuppression , incidence (geometry) , transplantation , population , antibody , immunology , antigen , physics , environmental health , optics
Background It is estimated that 25%‐35% of heart transplant recipients develop de novo donor‐specific antibodies (dnDSA). One factor that appears to play a role in clinical outcomes is DSA persistence. The objective of this study was to determine the incidence of transient and persistent dnDSA in a Canadian heart transplant population and to evaluate their impact on coronary allograft vasculopathy (CAV), graft function, and mortality. Methods A retrospective study of consecutive adult and transitioned pediatric heart transplant recipients (2008‐2015) in Toronto was performed. Clinical demographics were collected prospectively. HLA antibody testing was performed using Luminex single antigen assays. In statistical analysis, dnDSA was modeled as a time dependent covariate. Results During a median follow‐up of 4.1 years, dnDSA were detected in 42 (23%) with a median time to detection of 329 days (156‐740); 27 (64%) developed persistent dnDSA. Persistent dnDSA conferred an increased risk of death with a HR 4.0 (95%CI 1.4‐12.1) when adjusted recipient age, CAV, and cytomegalovirus status. Conclusions Transient dnDSA were not associated with adverse outcomes after heart transplantation. This suggests that transient dnDSA may not require enhanced immunosuppression, increased HLA antibody monitoring, or additional physiological assessment. By knowing the transient dnDSA status, clinicians may minimize both recipient morbidity and cost without increasing harm.